Ophthalmology

Review top news and interview highlights from the week ending March 25, 2022.

The professors and researchers from The University of Texas at Austin discussed new findings of Cas9 structure and mechanisms.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Viral vectors have become the most common method for delivering gene therapy; however, pre-existing humoral immunogenicity can potentially render a gene therapy ineffective.

Review top news and interview highlights from the week ending March 18, 2022.

The draft guidance from the Center for Biologics Evaluation and Research outlines safety considerations throughout the clinical development program timeline.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Christina Y. Weng, MD, MBA, Baylor College of Medicine, Houston, discussed therapies for macular degeneration.

Review top news and interview highlights from the week ending March 11, 2022.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Review top news and interview highlights from the week ending March 4, 2022.

David Taylor, PhD, an assistant professor in the department of molecular biosciences at UT Austin, discussed the Cas9 research conducted between 2 labs at UT Austin.

The decision is the latest action in a line of patent interferences over the revolutionary gene-editing technology.

The SARM1 gene is a key driver in the damage that ultimately leads to impaired vision.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The professor of ophthalmology from Radboud University, The Netherlands, discussed ongoing gene therapy trials in Stargardt disease.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The therapy has been well-tolerated in the 15 patients treated so far.

Researchers will use the model to study how lack of pigmentation affects RPE physiology and function.

The ophthalmologist from John A. Moran Eye Center discussed the close association between disease progression and uncovered risk alleles.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Investigators did not find any clinical signs of rejection of the mismatched donor cells.

The associate professor from UC San Diego discussed the curative potential of gene therapy in cystinosis.

The associate professor from Tufts University School of Medicine discussed the latest updates on the FOCUS trial.

Review top news and interview highlights from the week ending February 11, 2022.